Roche announces the promising results of an anticovid cocktail with Regeneron: 70% reduction in hospitalizations

The Swiss pharmaceutical group Roche unveiled on Tuesday promising results of clinical trials for the experimental cocktail of anticovid treatments combining the drugs casirivimab and imdevimab in which it collaborates with the American laboratory Regeneron for outpatients.

Data from a phase III study showed a 70% reduction in hospitalizations or deaths in patients with the disease who did not have to be hospitalized, the Swiss group reported in a statement, adding that they also showed a four-day reduction in symptom duration.

The data also indicated a reduction in the duration of symptoms by four days, from 14 to 10 days.Roche said.

This series of trials, which involved high-risk patients, evaluated treatments at doses of 2,400 mg and 1,200 mg, he explained.

This experimental treatment is the only combination of monoclonal antibodies that maintains its strength in the face of important new variants that are emerging.the Swiss laboratory said in the statement.

“New infections continue to rise globally with more than three million cases reported last week,” said Levi Garraway, medical director and global director of product development, quoted in the statement.

Garraway noted that “this experimental cocktail of antibodies may therefore offer hope for a potential new therapy for high-risk patients.”

The results of this series of tests will be quickly communicated to the health authorities. and submitted for examination by medical experts as soon as possible.

This experimental cocktail is the subject of several trials, still in progress, in particular for hospitalized patients. So far, around 25,000 people have taken part in the various stages of clinical studies.

KEEP READING: